Aileron Therapeutics Inc (ALRN) Given $19.33 Average Target Price by Brokerages

Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) have received a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price objective of $19.33 for the company and are anticipating that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also assigned Aileron Therapeutics an industry rank of 193 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised Aileron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th.

In other Aileron Therapeutics news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of Aileron Therapeutics stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $9.80, for a total transaction of $1,470,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 68.10% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new position in Aileron Therapeutics during the second quarter worth approximately $418,000. Citadel Advisors LLC acquired a new position in Aileron Therapeutics during the second quarter worth approximately $141,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Aileron Therapeutics in the 3rd quarter valued at approximately $165,000. Bank of New York Mellon Corp purchased a new position in shares of Aileron Therapeutics in the 3rd quarter valued at approximately $135,000. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $112,000. 7.57% of the stock is currently owned by institutional investors.

Shares of Aileron Therapeutics (NASDAQ ALRN) traded up $0.15 during midday trading on Friday, hitting $7.88. The stock had a trading volume of 14,936 shares, compared to its average volume of 20,642. Aileron Therapeutics has a 1-year low of $7.56 and a 1-year high of $15.48.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.07). research analysts forecast that Aileron Therapeutics will post -1.76 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Aileron Therapeutics Inc (ALRN) Given $19.33 Average Target Price by Brokerages” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2018/02/11/aileron-therapeutics-inc-alrn-given-19-33-average-target-price-by-brokerages.html.

About Aileron Therapeutics

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply